Who Supplies Fexofenadine to India from UNITED STATES

To import finished pharmaceutical formulations containing Fexofenadine into India, the importing company must obtain a Drug Import License from the Directorate General of Foreign Trade (DGFT). The Central Drugs Standard Control Organisation (CDSCO) requires registration of the product, which involves submitting Form 40/41 along with a No Objection Certificate (NOC) from the manufacturer. The registration process includes providing stability data in accordance with ICH Zone IV guidelines and ensuring compliance with the Indian Pharmacopoeia standards. The timeline for obtaining drug registration can vary but typically ranges from 6 to 12 months, depending on the completeness of the application and regulatory review processes.

Imported Fexofenadine formulations must undergo quality testing at CDSCO-approved laboratories. Each batch requires a Certificate of Analysis (CoA) confirming compliance with Indian Pharmacopoeia standards. Stability data must be provided, demonstrating the product's shelf-life under ICH Zone IV conditions. Upon arrival, customs drug inspectors conduct port inspections, which may include sampling and testing. If a batch fails quality testing, it may be rejected, re-exported, or destroyed, depending on the severity of the non-compliance.

Between 2024 and 2026, the CDSCO has implemented stricter regulations for the import of finished pharmaceutical formulations, including Fexofenadine. The Production Linked Incentive (PLI) scheme has been expanded to encourage domestic manufacturing, potentially affecting the volume of imports. Bilateral agreements between India and the United States have facilitated smoother trade processes, but compliance with updated regulatory standards remains mandatory.

India imports finished Fexofenadine formulations to meet the demand for branded and patented products not manufactured domestically. Specific dosage forms, such as extended-release tablets, are often sourced from international markets. The domestic capacity for producing these specialized formulations is limited, leading to a reliance on imports. The market size for Fexofenadine formulations in India is substantial, with a growing consumer base seeking effective antihistamines.

The Basic Customs Duty (BCD) for HS Code 30049039 is 10%. A Social Welfare Surcharge (SWS) of 10% is applied on the BCD, resulting in an additional 1% duty. Integrated Goods and Services Tax (IGST) is applicable, with the rate varying based on the product's classification and value. Anti-dumping duties may apply if the product is deemed to be imported at unfairly low prices. Exemption notifications can reduce the total landed duty, but these are subject to change and should be verified with the latest customs notifications.

India sources Fexofenadine formulations from the United States due to the availability of patented formulations and specialized dosage forms not produced domestically. The U.S. offers high-quality products that comply with international standards, providing a competitive advantage. Other suppliers, such as China and Germany, also export Fexofenadine formulations to India, but the United States maintains a significant share due to its advanced manufacturing capabilities and product innovation.

India imports Fexofenadine formulations from the United States due to the availability of patented and branded products that are not manufactured domestically. The U.S. offers specialized dosage forms, such as extended-release tablets, which are in demand in the Indian market. Additionally, technology-licensed products from the U.S. provide advanced formulations that meet international quality standards.

When compared to other origins like China and the European Union, the United States offers Fexofenadine formulations with superior quality, compliance with international regulatory standards, and innovative dosage forms. While China and the EU may offer competitive pricing, the U.S. maintains a unique advantage in terms of product quality and regulatory compliance.

Indian importers face risks such as single-source dependency, currency fluctuations, regulatory changes, and potential quality incidents. Shipping disruptions can also impact the supply chain. There have been instances of shortages due to manufacturing issues in the U.S., highlighting the need for diversified sourcing strategies.

1. 1Dual-Sourcing: Engage multiple suppliers to mitigate risks associated with single-source dependency.
2. 2Inventory Planning: Maintain adequate stock levels to buffer against supply chain disruptions.
3. 3Payment Terms: Negotiate favorable terms such as Letters of Credit (LC), Documents Against Acceptance (DA), or Documents Against Payment (DP) to manage financial exposure.
4. 4Minimum Order Quantities (MOQs): Align procurement volumes with market demand to optimize inventory costs.
5. 5Supplier Qualification: Conduct thorough due diligence to ensure suppliers meet quality and regulatory standards.

1. 1Obtain a valid Importer Exporter Code (IEC) from the DGFT.
2. 2Register the product with the CDSCO by submitting Form 40/41.
3. 3Secure a Drug Import License from the DGFT.
4. 4Obtain a No Objection Certificate (NOC) from the manufacturer.
5. 5Ensure compliance with customs regulations by engaging a licensed customs broker.
6. 6Seek an advance ruling for HS Code 30049039 to confirm classification and applicable duties.

1. 1Certificate of Analysis (CoA) confirming compliance with Indian Pharmacopoeia standards.
2. 2Certificate of Pharmaceutical Product (CoPP) issued by the regulatory authority in the U.S.
3. 3Good Manufacturing Practice (GMP) certificate.
4. 4Drug Master File (